Novonesis (Novozymes A/S)
26.2.2026 11:23:05 CET | Globenewswire | Press release
Trading by management and close relations of management
Trading by management and close relations of management
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.
The Executive Leadership Team members eligible for the Novozymes A/S 2023-2025 incentive program has on February 25, 2026, received the allocated shares. An overview of the number and value of shares allotted is provided on the following pages.
Please read the full announcement in PDF.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Kapitalforeningen SDG Invest26.2.2026 13:09:01 CET | Pressemeddelelse
Suspension i forbindelse med overflytning
Boehringer Ingelheim Limited26.2.2026 13:05:00 CET | Press release
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
Kapitalforeningen SDG Invest26.2.2026 13:03:36 CET | Pressemeddelelse
Kapitalforeningen SDG Invest - Årsrapport
Sitryx Therapeutics26.2.2026 13:00:00 CET | Press release
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
Amphista Therapeutics26.2.2026 13:00:00 CET | Press release
Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys® platform is delivering Targeted Glue™ degraders using novel E3 ligases into the clinic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom